Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.

Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC.

Pharmacogenomics. 2011 Mar;12(3):327-39. doi: 10.2217/pgs.10.191.

2.

The role of FKBP5 in cancer aetiology and chemoresistance.

Li L, Lou Z, Wang L.

Br J Cancer. 2011 Jan 4;104(1):19-23. doi: 10.1038/sj.bjc.6606014. Epub 2010 Nov 30. Review.

3.

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D.

Lancet Oncol. 2010 Jun;11(6):543-52. doi: 10.1016/S1470-2045(10)70090-5. Epub 2010 May 5.

4.

The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.

Jinwal UK, Koren J 3rd, Borysov SI, Schmid AB, Abisambra JF, Blair LJ, Johnson AG, Jones JR, Shults CL, O'Leary JC 3rd, Jin Y, Buchner J, Cox MB, Dickey CA.

J Neurosci. 2010 Jan 13;30(2):591-9. doi: 10.1523/JNEUROSCI.4815-09.2010.

5.

Emerging role of FKBP51 in AKT kinase/protein kinase B signaling.

Pei H, Lou Z, Wang L.

Cell Cycle. 2010 Jan 1;9(1):6-7. Epub 2010 Jan 9. No abstract available.

PMID:
20016266
6.

FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L.

Cancer Cell. 2009 Sep 8;16(3):259-66. doi: 10.1016/j.ccr.2009.07.016.

7.

Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.

Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, Wang L.

Cancer Res. 2008 Sep 1;68(17):7050-8. doi: 10.1158/0008-5472.CAN-08-0405.

Supplemental Content

Support Center